Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.

Abstract:

:Diquafosol ophthalmic solution 3 % (Diquas(®)) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye. In randomized, double-blind, multicentre trials in patients with dry eye, significantly greater improvements in fluorescein and rose bengal staining scores were seen with diquafosol ophthalmic solution 3 % than with placebo, and diquafosol ophthalmic solution 3 % was noninferior to sodium hyaluronate ophthalmic solution 0.1 % in terms of the improvement in the fluorescein staining score and more effective than sodium hyaluronate ophthalmic solution 0.1 % in terms of the improvement in the rose bengal staining score. The efficacy of diquafosol ophthalmic solution 3 % in the treatment of dry eye was maintained in the longer term, with improvements also seen in subjective dry eye symptoms, and was also shown in a real-world setting. Diquafosol ophthalmic solution 3 % also demonstrated efficacy in various specific dry eye disorders, including aqueous-deficient dry eye, short tear film break-up time dry eye, obstructive meibomian gland dysfunction, dry eye following laser in situ keratomileusis surgery and dry eye following cataract surgery, as well as in contact lens wearers and visual display terminal users. Diquafosol ophthalmic solution 3 % was generally well tolerated in patients with dry eye, with eye irritation the most commonly reported adverse event. In conclusion, diquafosol ophthalmic solution 3 % is a useful option for the treatment of dry eye.

journal_name

Drugs

journal_title

Drugs

authors

Keating GM

doi

10.1007/s40265-015-0409-7

subject

Has Abstract

pub_date

2015-05-01 00:00:00

pages

911-22

issue

8

eissn

0012-6667

issn

1179-1950

journal_volume

75

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Candesartan cilexetil: an update of its use in essential hypertension.

    abstract:UNLABELLED:Candesartan cilexetil is converted to the angiotensin II receptor antagonist candesartan during absorption from the gastrointestinal tract. The selective and competitive binding of candesartan to the angiotensin II type 1 (AT(1)) receptor prevents binding of angiotensin II, a key mediator in the renin-angiot...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262080-00016

    authors: Easthope SE,Jarvis B

    更新日期:2002-01-01 00:00:00

  • Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

    abstract::When used to treat patients with Parkinson's disease pergolide acts at dopamine receptors in the corpus striatum to improve locomotor activity, reducing the tremor, gait disturbances, bradykinesia or akinesia and rigidity experienced by such patients. Treatment with pergolide often allows substantial reductions in con...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199039030-00009

    authors: Langtry HD,Clissold SP

    更新日期:1990-03-01 00:00:00

  • What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?

    abstract::The newest (third generation) fluoroquinolones are potentially useful agents in the management of community-acquired respiratory tract infections. This is mainly due to their increased activity against Streptococcuspneumoniae, a pathogen poorly susceptible to the second-generation compounds, and playing a major role i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957060-00002

    authors: Momméja-Marin H,Carbon C

    更新日期:1999-06-01 00:00:00

  • Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases.

    abstract:INTRODUCTION:Authorization of orphan medicinal products (OMPs) is often based on studies with several methodological shortcomings. Hence, data are difficult to interpret and efficacy does not always correspond to real-world effectiveness. We investigated to what extent an efficacy-effectiveness gap exists for OMPs for ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-017-0788-z

    authors: Schuller Y,Hollak CEM,Gispen-de Wied CC,Stoyanova-Beninska V,Biegstraaten M

    更新日期:2017-09-01 00:00:00

  • Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

    abstract::Sitagliptin (Januvia(®), Xelevia™, Glactiv(®), Tesavel(®)) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Numerous randomized placebo- or active comparator-c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0169-1

    authors: Plosker GL

    更新日期:2014-02-01 00:00:00

  • HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study.

    abstract::The aim of the Helsinki Heart Study, a 5-year primary prevention placebo-controlled study involving 4081 dyslipidaemic men (aged 40 to 55 years), was to investigate if increasing high density lipoprotein (HDL)-cholesterol plasma levels and decreasing low density lipoprotein (LDL)-cholesterol levels would reduce the in...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199000401-00004

    authors: Frick MH,Manninen V,Huttunen JK,Heinonen OP,Tenkanen L,Mänttäri M

    更新日期:1990-01-01 00:00:00

  • The role of arachidonic acid metabolites in gastrointestinal homeostasis. Biochemical, histological and clinical gastrointestinal effects.

    abstract::Metabolites of arachidonic acid have a broad range of physiological functions in the gastrointestinal tract, and seem to be involved in certain disturbances of gastrointestinal integrity and function. Prostaglandins inhibit gastric acid secretion, apparently via an adenylate cyclase-linked receptor, and also stimulate...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700331-00007

    authors: Isselbacher KJ

    更新日期:1987-01-01 00:00:00

  • Current management of mantle cell lymphoma.

    abstract::Mantle cell lymphoma is a rare yet well defined subtype of B-cell non-Hodgkin's lymphoma. The correct histological diagnosis of this lymphoma subtype is of the utmost importance; however, it is also a very difficult diagnosis. Clinical management is often complex, and despite the successful introduction of monoclonal ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767120-00004

    authors: Weigert O,Unterhalt M,Hiddemann W,Dreyling M

    更新日期:2007-01-01 00:00:00

  • Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.

    abstract::Sitagliptin (Januvia, Glactiv(R), Tesavel(R)) is a dipeptidyl peptidase-4 inhibitor indicated for the treatment of type 2 diabetes mellitus. Oral sitagliptin as monotherapy or combination therapy was generally well tolerated and improved glycaemic control in well designed clinical trials in patients with type 2 diabet...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11203790-000000000-00000

    authors: Dhillon S

    更新日期:2010-03-05 00:00:00

  • [Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].

    abstract::During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856002-00004

    authors: Krivitzky A,Nguyen G,Gaudouen Y,Legrand M,Cohen R

    更新日期:1998-01-01 00:00:00

  • Desirable therapeutic characteristics of an optimal antihypertensive agent.

    abstract::Hypertension affects 65 million people in the US, and is a major cause of morbidity and mortality, but less than one-third of patients with hypertension are treated to goal blood pressure. Multiple factors have been cited, and include suboptimal adherence to treatment and lifestyle modifications, limited access to hea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666090-00006

    authors: Mustone Alexander L

    更新日期:2006-01-01 00:00:00

  • Hypertension in pregnancy. Pathophysiology and management.

    abstract::Hypertension in pregnancy has implications for both maternal and fetal welfare. Extrapolation from concepts of mechanisms operating in hypertension in general to pregnancy-related hypertension is not justified. In the latter, the major features are a hyper-adrenergic state, plasma volume reduction and an increased sys...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198428020-00005

    authors: Lubbe WF

    更新日期:1984-08-01 00:00:00

  • Enoxaparin. A review of its clinical potential in the management of coronary artery disease.

    abstract:UNLABELLED:Enoxaparin (enoxaparin sodium) is a low molecular weight heparin (LMWH) that is widely used in the prevention of deep venous thrombosis and pulmonary embolism in patients undergoing orthopaedic or general surgery. Its efficacy in these indications has led to study of its use in patients with coronary artery ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856020-00013

    authors: Noble S,Spencer CM

    更新日期:1998-08-01 00:00:00

  • Current, new and future treatments in dyslipidaemia and atherosclerosis.

    abstract::The new therapeutic options available to clinicians treating dyslipidaemia in the last decade have enabled effective treatment for many patients. The development of the HMG-CoA reductase inhibitors (statins) have been a major advance in that they possess multiple pharmacological effects (pleiotropic effects) resulting...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060010-00005

    authors: Chong PH,Bachenheimer BS

    更新日期:2000-07-01 00:00:00

  • Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.

    abstract::ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01164-3

    authors: Morris TA,Khoo C,Solomon BJ

    更新日期:2019-08-01 00:00:00

  • Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

    abstract::Nizatidine is an H2-receptor antagonist which in animal studies was more active on a weight-for-weight basis than cimetidine in inhibiting basal and stimulated gastric acid secretion. Similarly, studies in humans have confirmed that nizatidine is a potent inhibitor of basal, nocturnal and stimulated gastric acid secre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836050-00002

    authors: Price AH,Brogden RN

    更新日期:1988-11-01 00:00:00

  • Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

    abstract::Bevacizumab is a recombinant, humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody that neutralizes the biological activity of VEGF and inhibits tumour angiogenesis. In two pivotal, well designed, phase III, clinical trials (GOG-0218 and ICON7) in women with advanced epithelial ovarian, fallopi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208940-000000000-00000

    authors: Dhillon S

    更新日期:2012-05-07 00:00:00

  • Inflammatory bowel disease management. Some thoughts on future drug developments.

    abstract::This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753020-00001

    authors: Rhodes J,Thomas G,Evans BK

    更新日期:1997-02-01 00:00:00

  • Chemotherapeutic induction of labour. A rational approach.

    abstract::Induction of labour, defined as stimulation of uterine contractions before the spontaneous onset of labour, is indicated when the condition of the mother or fetus precludes awaiting the onset of spontaneous labour. In current medical practice, induction of labour comprises 2 phases: cervical priming and induction of c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754010-00005

    authors: Xenakis EM,Piper JM

    更新日期:1997-07-01 00:00:00

  • Desloratadine.

    abstract::Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers. Therapeutic dosages had no effects on wakefulness or psycho...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200161060-00007

    authors: McClellan K,Jarvis B

    更新日期:2001-01-01 00:00:00

  • Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

    abstract::Developments in drug delivery technology have expanded the formulations of 5-aminosalicylic acid (5-ASA) available to clinicians over the last 50 years. Delivery of adequate doses of 5-ASA to the colon can be achieved by pH-dependent, delayed-release or pro-drug formulations. Despite some variations in the pharmacokin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868080-00006

    authors: Fernandez-Becker NQ,Moss AC

    更新日期:2008-01-01 00:00:00

  • Effects of non-narcotic analgesics on the liver.

    abstract::Serious hepatotoxicity is uncommon with the proper therapeutic use of non-narcotic analgesics but experience with new non-steroidal anti-inflammatory drugs (NSAIDs) is limited. Drugs such as ibufenac, fenclofenac and benoxaprofen were withdrawn from the market because of hepatotoxicity, and liver damage has been repor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600324-00010

    authors: Prescott LF

    更新日期:1986-01-01 00:00:00

  • Acamprosate: A Review of Its Use in Alcohol Dependence.

    abstract::Acamprosate (Campral(®), Aotal(®), Regtect(®)) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0423-9

    authors: Plosker GL

    更新日期:2015-07-01 00:00:00

  • In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.

    abstract::Antibacterial activities of cefotaxime and its major metabolite, desacetylcefotaxime, against 178 strains (of 10 species) were assessed in terms of minimum inhibitory concentrations (MIC50 and MIC80), and were compared with those of cefoperazone and ceftazidime. The activity of desacetylcefotaxime was several times le...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198800352-00013

    authors: Oizumi K,Hayashi I,Aonuma S,Konno K

    更新日期:1988-01-01 00:00:00

  • Dual inhibitory action of nedocromil sodium on antigen-induced inflammation.

    abstract::In human lung tissue in vitro, nedocromil sodium inhibited the release of histamine and leukotrienes induced by anti-IgE, as well as the contraction of isolated bronchi which followed this challenge. In the hamster cheek pouch in vivo, nedocromil sodium inhibited the inflammatory response induced by challenge with eit...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198900371-00013

    authors: Dahlén SE,Björck T,Kumlin M,Sydbom A,Raud J,Palmertz U,Franzén L,Grönneberg R,Hedqvist P

    更新日期:1989-01-01 00:00:00

  • Letermovir: First Global Approval.

    abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0860-8

    authors: Kim ES

    更新日期:2018-01-01 00:00:00

  • Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.

    abstract::The advent of thrombolytic therapy was a major advance in the treatment of ST-segment elevation myocardial infarction (STEMI). The administration of fibrinolytic reperfusion therapy can reduce mortality rates by as much as 30%, with the greatest benefit observed if therapy is administered soon after symptom onset. Out...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11317670-000000000-00000

    authors: Morse MA,Todd JW,Stouffer GA

    更新日期:2009-10-01 00:00:00

  • Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia.

    abstract::Trigeminal neuralgia is a representative neuropathic facial pain condition, characterised by unilateral paroxysmal pain in the distribution territory of one or more divisions of the trigeminal nerve, triggered by innocuous stimuli. A subgroup of patients with trigeminal neuralgia [TN (previously defined as atypical TN...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0964-9

    authors: Di Stefano G,Truini A,Cruccu G

    更新日期:2018-09-01 00:00:00

  • Cenegermin: A Review in Neurotrophic Keratitis.

    abstract::Cenegermin (Oxervate™), an ophthalmic solution containing 20 µg/mL of recombinant human nerve growth factor (rhNGF), is the first drug to be approved for the treatment of neurotrophic keratitis (NK; also referred to as neurotrophic keratopathy). In the registration trials, the majority of adults with moderate or sever...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01289-w

    authors: Deeks ED,Lamb YN

    更新日期:2020-04-01 00:00:00

  • Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.

    abstract::The article Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817-1828 Gilead Sciences requested that the article be Open Choice to make the article an open ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-019-01101-4

    authors: Deeks ED

    更新日期:2019-04-01 00:00:00